– This randomised, double-blind, placebo-controlled trial was designed to assess the safety, tolerability, and efficacy of NLY01 in subjects with early, untreated PD. – The primary endpoint, change from baseline in the sum of MDS-UPDRS Parts II and III after 36 weeks of NLY01 treatment, compared with placebo, did not reach statistical significance. – Age was identified as a significant…
Category: parkinson’s disease
New real-world data for ONGENTYS®▼ (opicapone) released at the MDS
New data presented 12-16 September at the MDS 2020 Virtual Congress further support the efficacy and tolerability of ONGENTYS® (opicapone) observed in pivotal Phase III studies. Opicapone is a once-daily catechol-O-methyltransferase (COMT) inhibitor, approved for the treatment of end-of-dose motor fluctuations in adult PD patients taking levodopa. Data from OPTIPARK study demonstrated consistently low incidence of treatment-related adverse events in clinical practice from the…
Topline results of Phase 1-2 CDNF trial
Industry news from Herantis Pharma
MasterClass on the non-oral therapies and new NICE guideline for Parkinson’s
With publication of the new NICE guideline for Parkinson’s, Parkinson’s Academy is holding a series of roadshows exploring the non-oral therapy pathway in detail
In Parkinson’s disease, patients may suffer from delayed ON as well as wearing OFF – which is more important?
Report from Britannia Pharmaceuticals on their plenary session on PD treatment, held at the 9th CONy Congress in Budapest, Hungary, March 2015
